Background: One of the most problematic expression of ageing is frailty, and an approach based on its early identification is mandatory. The Sunfrail-tool (ST), a 9-item questionnaire, is a promising instrument for screening frailty.
Aims: To assess the diagnostic accuracy and the construct validity between the ST and a Comprehensive Geriatric Assessment (CGA), composed by six tests representative of the bio-psycho-social model of frailty; To verify the discriminating power of five key-questions of the ST; To investigate the role of the ST in a clinical-pathway of falls' prevention.
Methods: In this retrospective study, we enrolled 235 patients from the Frailty-Multimorbidity Lab of the University-Hospital of Parma. The STs' answers were obtained from the patient's clinical information. A patient was considered frail if at least one of the CGAs' tests resulted positive.
Results: The ST was associated with the CGA's judgement with an Area Under the Curve of 0.691 (CI 95%: 0.591-0.791). Each CGA's test was associated with the ST total score. The five key-question showed a potential discriminating power in the CGA's tests of the corresponding domains. The fall-related question of the ST was significantly associated with the Short Physical Performance Battery total score (OR: 0.839, CI 95%: 0.766-0.918), a proxy of the risk of falling.
Discussion: The results suggest that the ST can capture the complexity of frailty. The ST showed a good discriminating power, and it can guide a second-level assessment to key frailty domains and/or clinical pathways.
Conclusions: The ST is a valid and easy-to-use instrument for the screening of frailty.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8847239 | PMC |
| http://dx.doi.org/10.1007/s40520-021-01931-x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Background: The early diagnosis and monitoring of Alzheimer's disease (AD) presents a significant challenge due to its heterogeneous nature, which includes variability in cognitive symptoms, diagnostic test results, and progression rates. This study aims to enhance the understanding of AD progression by integrating neuroimaging metrics with demographic data using a novel machine learning technique.
Method: We used supervised Variational Autoencoders (VAEs), a generative AI method, to analyze high-dimensional neuroimaging data for AD progression, incorporating age and gender as covariates.
Biomarkers.
Alzheimers Dement
December 2024
Department of Psychiatry and Human Behavior, University of California, Irvine, Irvine, CA, USA.
Background: Aging is associated with disruptions in non-rapid eye movement (NREM) sleep and memory decline. Cerebral small vessel disease (CSVD) increases with age and is associated with clinical sleep disturbance, but little is known about its relationship with local expression of NREM sleep. Here, we explore associations between CSVD burden, memory, and local electroencephalography (EEG) measures during NREM sleep in older adults.
View Article and Find Full Text PDFBackground: Structural and functional heterogeneity in the brains of patients with Alzheimer's disease (AD) leads to diagnostic and prognostic uncertainty and confounds clinical treatment planning. Normative modelling, where individual-level deviations in brain measures from a reference sample are computed to infer personalized effects of disease, allows parsing of disease heterogeneity. In this study, GAN based normative modelling technique quantifies individual level neuroanatomical abnormality thereby facilitating measurement of personalized disease related effects in AD patients.
View Article and Find Full Text PDFBackground: Current tools for Alzheimer's disease screening and staging used in clinical research (e.g. ACE-3, ADAS-Cog) require substantial face-to-face time with trained professionals, and may be affected by subjectivity, "white coat syndrome" and other biases.
View Article and Find Full Text PDFBiomarkers.
Alzheimers Dement
December 2024
Boston University Chobanian & Avedisian School of Medicine, Boston, MA, USA.
Background: Plasma-based biomarkers are emerging as a new diagnostic tool for Alzheimer's disease (AD) with high accuracy and low cost. Whether aggregated plasma protein risk score (PPRS) derived from a single sample could be useful for diagnosis of incident mild cognitive impairment (MCI) and AD is uncertain. This study aims to understand the association between PPRS and future risk of AD related outcomes.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!